PlainRecalls
FDA Drug Low Class III Terminated

Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.

Reported: October 4, 2023 Initiated: September 12, 2023 #D-1178-2023

Product Description

Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.

Reason for Recall

Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.

Details

Recalling Firm
Tolmar, Inc.
Units Affected
2990 cartons
Distribution
Nationwide in the US.
Location
Fort Collins, CO

Frequently Asked Questions

What product was recalled?
Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.. Recalled by Tolmar, Inc.. Units affected: 2990 cartons.
Why was this product recalled?
Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 4, 2023. Severity: Low. Recall number: D-1178-2023.